%0 Journal Article %T Twice-daily chemoradiotherapy must still be the choice for patients with limited-stage small-cell lung cancer %A Franco, Fernando %A Pérez-Callejo, David %A Provencio, Mariano %J Journal of Thoracic Disease %D 2017 %B 2017 %9 %! Twice-daily chemoradiotherapy must still be the choice for patients with limited-stage small-cell lung cancer %K %X At the time of diagnosis, 30% of patients with small cell lung carcinoma (SCLC) present a limited stage of disease, which is now called I-IIIB (IASLC). However, the outcome of limited-stage SCLC remains poor, with a median survival of 16 to 24 months using current treatments, and only 15–25% of long-term survivors. %U https://jtd.amegroups.org/article/view/15547 %V 9 %N 9 %P 2843-2846 %@ 2077-6624